FDA warned Pico IV Inc. that its intravenous CBD product Pico IV is an unapproved new drug sold with drug claims.
What happened
FDA reviewed www.picoiv.com in January 2024 and the company’s Facebook and Instagram pages. FDA found that the website and linked social media offered “Pico IV,” an intravenous CBD product, directed consumers to the website to purchase it, and included posts and testimonials claiming it could treat or ease conditions such as pain, anxiety, inflammation, sleep problems, and Crohn’s disease. FDA says the product is a drug and an unapproved new drug.
What FDA found
Pico IV is an unapproved new drug because it is introduced into interstate commerce without an FDA-approved application.
Sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)Pico IV is not a dietary supplement because the law defines a dietary supplement as intended for ingestion, and Pico IV is given intravenously.
Section 201(ff)(2)(A)(i), 21 U.S.C. 321(ff)(2)(A)(i)Pico IV is a drug because the website and social media claims show it is intended to treat, cure, mitigate, or prevent disease or affect body structure or function.
Section 201(g)(1), 21 U.S.C. 321(g)(1)Pico IV is a new drug because it is not generally recognized as safe and effective for the claimed uses.
Section 201(p), 21 U.S.C. 321(p)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the steps taken to correct the violations, including an explanation, prevention steps, and related documents. If the company believes the product is not in violation, it must include its reasoning and supporting information; if corrective action cannot be completed in that time, it must state why and give a completion date.
Who should pay attention
- clinics and med spas that offer or consider IV CBD infusions
- consumers buying injectable CBD online
- companies making or supplying injectable CBD products
This is a summary. Read the original letter on fda.gov.